Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
80 studies found for:    "Monoclonal gammopathy of undetermined significance"
Show Display Options
Rank Status Study
1 Suspended Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
Conditions: Neuropathy;   Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
Intervention: Drug: Lenalidomide
2 Completed Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
Conditions: Smoldering Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention:
3 Recruiting Unravel MGUS (Monoclonal Gammopathy of Unknown Significance)
Condition: Monoclonal Gammopathy of Unknown Significance
Interventions: Other: Blood sample taken;   Other: Answering a lifestyle questionnaire;   Other: Phone call from researcher
4 Completed A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Biological: Siltuximab
5 Completed Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy
Conditions: Monoclonal Gammopathy;   Monoclonal Gammopathy of Undetermined Signification;   Myeloma
Intervention: Other: blood and bone marrow samples
6 Active, not recruiting Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Smoldering Myeloma
Intervention: Genetic: Genetic study of DNA copies
7 Recruiting Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies
Conditions: Monoclonal Gammopathy of Unknown Significance;   Smoldering Multiple Myeloma
Intervention: Procedure: Blood Collection
8 Terminated
Has Results
Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
Condition: Precancerous Condition
Intervention: Biological: Rituximab
9 Not yet recruiting Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
Conditions: Monoclonal Gammopathies;   Overweight;   Obesity
Intervention: Drug: Liraglutide
10 Completed
Has Results
Imaging in MGUS, SMM and MM
Conditions: Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Interventions: Drug: 18-NaF PET;   Other: DCE-MRI;   Drug: 18-FDG PET/CT
11 Recruiting Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Smoldering Multiple Myeloma
Intervention: Behavioral: Relaxation Response Resiliency Program (3RP)
12 Completed
Has Results
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Smoldering Multiple Myeloma
Interventions: Drug: celecoxib;   Drug: placebo;   Other: laboratory biomarker analysis
13 Completed S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
Conditions: Multiple Myeloma;   Plasma Cell Myeloma;   Precancerous Condition
Interventions: Genetic: cytogenetic analysis;   Genetic: microarray analysis;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
14 Completed RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
Condition: Polyneuropathy
Intervention: Drug: Rituximab
15 Unknown  Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis
Conditions: Monoclonal Gammopathy;   Tuberculosis
Intervention:
16 Terminated
Has Results
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
Interventions: Dietary Supplement: defined green tea catechin extract;   Genetic: gene expression analysis;   Genetic: protein analysis;   Other: laboratory biomarker analysis
17 Withdrawn Imaging Studies and the Development of Multiple Myeloma
Conditions: Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention: Drug: Fluciclatide
18 Recruiting A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early
Conditions: Plasma Cell Dyscrasia;   Monoclonal Gammopathy
Intervention:
19 Terminated
Has Results
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Smoldering Multiple Myeloma;   Chronic Lymphocytic Leukemia
Intervention: Dietary Supplement: Omega 3 Fatty Acid
20 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.